OncoMatch/Clinical Trials/NCT06567743
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Is NCT06567743 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cretostimogene Grenadenorepvec for high-risk non-muscle-invasive bladder cancer.
Treatment: Cretostimogene Grenadenorepvec — This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CIS
Excluded: Stage MUSCLE-INVASIVE, III, IV
Grade: high-grade
CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease without CIS
Prior therapy
Must have received: BCG — naïve
BCG-naïve high-risk high-grade NMIBC
Cannot have received: gemcitabine
Cohort CX Only: serial intravesical gemcitabine within 24 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Arizona Urology Specialty · Tucson, Arizona
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Arkansas Urology · Little Rock, Arkansas
- Michael G Oefelein, MD Clinical Trials · Bakersfield, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06567743 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gemcitabine disqualifies patients from enrollment.
What disease stage is eligible?
Stage CIS is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages